Ever-advancing chronic myeloid leukemia treatment-Reference-Cited by-同舟云学术

Ever-advancing chronic myeloid leukemia treatment

Published:2013-11-22 Issue:1 Volume:19 Page:3-9
ISSN:1341-9625
Container-title:International Journal of Clinical Oncology
language:en
Short-container-title:Int J Clin Oncol

Author:

Kimura Shinya,Ando Toshihiko,Kojima Kensuke

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Hematology,General Medicine,Surgery

Link

http://link.springer.com/content/pdf/10.1007/s10147-013-0641-7.pdf

Reference31 articles.

1. Druker BJ, Talpaz M, Resta DJ et al (2001) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344:1031–1037

2. O’Brien SG, Guilhot F, Larson RA et al (2003) Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348:994–1104

3. Baccarani M, Deininger MW, Rosti G et al (2013) European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 122:872–884

4. O’Brien S, Abboud CN, Akhtari M et al (2012) NCCN Clinical Practice Guidelines in Oncology: Chronic Myelogenous Leukemia. Version 2, 2013. Available at: NCCN.org. Accessed Sep 17, 2012

5. Deininger M, O’Brien SG, Guilhot F et al (2009) International randomized study of Interferon vs STI571 (IRIS) 8-year follow up: Sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib. Blood 114:462 (Abstract 1126)

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Chronic myeloid leukaemia with soft tissue mass formed by mature granulocytes;BMJ Case Reports;2024-06

2. Ponatinib: An update on its drug targets, therapeutic potential and safety;Biochimica et Biophysica Acta (BBA) - Reviews on Cancer;2023-09

3. Cancer Chemoresistance; Recent Challenges and Future Considerations;Therapeutic Approaches in Cancer Treatment;2023

4. Discovery and characterization of novel potent BCR-ABL degraders by conjugating allosteric inhibitor;European Journal of Medicinal Chemistry;2022-12

5. Folic Acid-Appended Hydroxypropyl-β-Cyclodextrin Exhibits Potent Antitumor Activity in Chronic Myeloid Leukemia Cells via Autophagic Cell Death;Cancers;2021-10-28